Progesterone Receptor Agonists and Antagonists as Anticancer Agents

被引：3
|
作者：
Chakraborty, A. [1 ]
Chatterjee, S. [1 ]
Roy, P. [1 ]
机构：
[1] Indian Inst Technol Roorkee, Dept Biotechnol, Mol Endocrinol Lab, Roorkee 247667, Uttar Pradesh, India
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2010年 / 10卷 / 06期
关键词：
Progesterone receptor; progestagens; agonists; antagonists; anti-cancer; HORMONE REPLACEMENT THERAPY; BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; PENICILLIUM-OBLATUM; INHIBITORY FUNCTION; ENDOMETRIAL CANCER; SIGNALING PATHWAYS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION;
D O I：
10.2174/138955710791384108
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Progesterone is a major female steroid hormone produced by the ovarian corpus luteum and by the placental syncyiotrophoblast during the second trimester. The biological effects of this steroid hormone are mediated by the ubiquitously expressed progesterone receptor. The exact link between progesterone and female reproductive organ cancer is a controversial issue with various cross-talks. The present review summarizes recent trends in the development of some (anti) progestagen in the cure and management of breast and uterine cancers.
引用
收藏
页码：506 / 517
页数：12
相关论文
共 50 条
  • [31] A multiplexed screening method for agonists and antagonists of the estrogen receptor protein
    Zhonghui Li
    Ming Yan
    Zhoumin Li
    Maika Vuki
    Dan Wu
    Fei Liu
    Wenying Zhong
    Luyong Zhang
    Danke Xu
    Analytical and Bioanalytical Chemistry, 2012, 403 : 1373 - 1384
  • [32] Lysophosphatidic acid receptor agonists and antagonists (WO2010051053)
    Parrill, Abby L.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (02) : 281 - 286
  • [33] Progesterone Receptor Signaling Mechanisms
    Grimm, Sandra L.
    Hartig, Sean M.
    Edwards, Dean P.
    JOURNAL OF MOLECULAR BIOLOGY, 2016, 428 (19) : 3831 - 3849
  • [34] Small molecule antagonists of the MDM2 oncoprotein as anticancer agents
    Buolamwini, JK
    Addo, J
    Kamath, S
    Patil, S
    Mason, D
    Ores, M
    CURRENT CANCER DRUG TARGETS, 2005, 5 (01) : 57 - 68
  • [35] Signaling inputs to progesterone receptor gene regulation and promoter selectivity
    Daniel, Andrea R.
    Knutson, Todd P.
    Lange, Carol A.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 308 (1-2) : 47 - 52
  • [36] P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future
    Borah, Pobitra
    Deka, Satyendra
    Mailavaram, Raghu Prasad
    Deb, Pran Kishore
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (26) : 2792 - 2807
  • [37] Effects of histamine H2 receptor agonists and antagonists on the isolated guinea pig gallbladder
    Coruzzi, G
    Pozzoli, C
    Poli, E
    Coppelli, G
    Bertaccini, G
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (01) : 84 - 90
  • [38] Fusion estrogen receptor proteins: toward the development of receptor-based agonists and antagonists
    Muyan, M
    Yi, P
    Sathya, G
    Willmert, LJ
    Driscoll, MD
    Hilf, R
    Bambara, RA
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 182 (02) : 249 - 263
  • [39] Synthesis, pharmacological evaluation and docking studies of progesterone and testosterone derivatives as anticancer agents
    Jabeen, Muafia
    Choudhry, Muhammad Iqbal
    Miana, Ghulam Abbas
    Rahman, Khondaker Miraz
    Rashid, Umer
    Khan, Hidayat-ullah
    Arshia
    Sadiq, Abdul
    STEROIDS, 2018, 136 : 22 - 31
  • [40] Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review
    Begam, A. Jameera
    Jubie, S.
    Nanjan, M. J.
    BIOORGANIC CHEMISTRY, 2017, 71 : 257 - 274
12345